Roche’s Second-Quarter Sales Held Back by Blockbuster Eye Drug

Roche reported Q2 revenue of 15.6B CHF ($19.2B), roughly in line with the 15.5B CHF analyst estimate, but the key issue was Vabysmo’s slower-than-expected recovery. Vabysmo revenue fell in the US at constant exchange rates, linked to a weaker patient-access environment after a rival stopped funding patient-support foundations. Investors are still looking to a new eye drug to power growth, keeping near-term sentiment cautious.

Analysis

The important signal is not the quarter itself; it is that Roche still appears overly levered to a single ophthalmology franchise while the next growth engine remains more hope than proof. In this setup, any moderation in Vabysmo share gains matters disproportionately because it forces the market to lean harder on pipeline execution, which typically compresses the multiple before it shows up in revenue. The street likely still prices in a smoother glide path than the US access/channel dynamics can support.

Second-order, this is a reminder that retina competition is partly an access-and-rebate war, not just a clinical one. If patient-support changes did not translate into a cleaner step-up, then the category may be less elastic than bulls assume, which is bad for near-term share acceleration at Roche and potentially good for incumbents that already have entrenched prescriber habits. Over 1-3 months, the key catalyst is whether sequential US growth reaccelerates; over 6-18 months, the issue is whether the new-drug launch can offset a Vabysmo plateau without margin dilution.

Contrarian view: this may be more noise than thesis break, because foundation/funding changes can distort a single quarter and then normalize. The stock should only stay under pressure if management has to narrow growth assumptions or if Vabysmo fails to regain momentum despite easier access conditions. Falsifier: a clear sequential re-acceleration in US Vabysmo or materially better-than-expected uptake of the next launch.

Key Decisions for Investors

• Short RHHBY on strength over the next 1-2 weeks; use the rally to express concern that one franchise is still carrying too much of the growth narrative. Risk/reward improves if the market is extrapolating Vabysmo recovery too aggressively.
• If using options, buy 3-6 month RHHBY put spreads rather than outright puts; the downside thesis is real but likely capped by Roche's diversified base and pipeline optionality. Falsify the trade if management guides to re-acceleration in the retina franchise.
• Pair trade: short RHHBY / long XLV for 1-3 months to isolate company-specific execution risk versus broader healthcare sentiment. This is cleaner than a directional sector short because the issue is idiosyncratic growth quality, not a sector macro problem.
• Set an alert for next-quarter US Vabysmo sequential growth and any change in launch commentary on the key new drug; if either inflects positively, cover 50% of the short. If not, the stock likely remains a multiple compression story into year-end.